How do we do it?

The science behind the tests

How it works

Testing & Detection

Test/Detection Principle for Raybiotech kit is Immunochromatography, the separation of
components in a mixture through a medium using capillary force and the specific and rapid binding of an antibody to its antigen. Each cassette is a dry medium that has been coated separately with novel coronavirus N protein and anti-mouse antibody. The cassette contains two separate strips and sample pads (one for detection of IgM antibodies and one for detection of IgG antibodies). Free colloidal gold-labeled anti-human IgM and IgG are in the release pad section. Once diluted serum or whole blood is applied to the release pad section, the anti-human IgM and IgG antibodies bind to coronavirus IgM and IgG antibodies if present, forming an Ig-IgM or Ig-IgG complex.

The sample and antibodies move across the cassette’s medium via capillary action. If the coronavirus IgM or IgG are present in the sample, the test line will be bound by the Ig-IgM or Ig-IgG complex and develop color. If there is no coronavirus IgM or IgG antibodies in the sample, free anti-human IgM or free anti-human IgG will not bind to the test line and no color will
develop. The free anti-human IgM or free anti-human IgG antibodies will bind to the control lines; these
control lines should be visible after the detection step to confirm the kit is working properly.

Screen      Test       Treat

Rapid Test Kit

Overall Accuracy


Sample size


Nasal Swab Test

Science Behind Covid-19


Emerging evidence in COVID-19 suggests that the SARS-CoV-2 virus that employs pathogen evasion
strategies against macrophages, including delaying macrophage activation and inflecting and killing
macrophages. The capacity to delay the innate immune response is consistent with the observation
that host infection can occur two to fourteen days before the onset of symptoms.
In SARS-CoV-2 infection, if macrophages and DCs are being destroyed by the virus before they can
initiate effective antigen presentation to activate the adaptive immune system, those with the
highest viral loads might be expected to do most poorly. Higher viral loads would be expected to
destroy more macrophages and DCs and to more decisively inhibit the immune activation
necessary to get ahead of the virus. This might contribute to understanding of why health care
workers, who are potentially exposed to larger volumes of viral load, from repeated exposure to
infected patients, would have greater risk of severe disease as has been observed.


Respiratory tract infections (RTIs) are the most common, and potentially most severe, of infections treated by
healthcare practitioners. Lower RTIs along with influenza, are the most common cause of death by infection in
the United States. Identifying the causative pathogen(s) rapidly and accurately is key in deciding on a proper
treatment protocol. Advanced Biotech Rx offers a new solution to pathogen detection in RTIs. Real-Time
Polymerase Chain Reaction for Respiratory Tract Microbiota (qPCR).
Using the latest molecular biology techniques, ABRx is able to use the genetic material of the pathogen (DNA,
RNA) to accurately identify the species of the pathogen and to detect resistance genes expressed by the
pathogen to certain pharmacotherapies.
This rapid and accurate identification of the causative agent of upper respiratory tract infections
may improve patient care and management by informing timely and effective antibiotic or antiviral therapy,
preventing secondary spread of infection, shortening hospital stays and reducing the cost of unnecessary
ancillary testing. The Limitless Diagnostics Respiratory Pathogen Profile is PCR based and tests for 17 viruses
and 3 bacteria that cause upper respiratory infections. Limitless Diagnostics utilizes the BioFire respiratory
platform which has demonstrated a sensitivity of 97.1% and a specificity of 99.3%.

Get In Touch

    Share This